Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
Status:
Active, not recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
This study will look at how effective the study drug (tepotinib) is at stopping the growth
and spread of lung cancer. This study will also measure a number of other things including
safety of the study drug and the side effects, how body processes the study drug, or how the
study drug affects your quality of life. The study also has an optional pharmacogenetic
research part. Pharmacogenetic research is an important way to try to understand the role of
genetics in human disease and how genes impact the effectiveness of drugs, because
differences in genes can change the way a person responds to a particular drug.